17.04.2018
Wacker Chemie AG DE000WCH8881
DGAP-News: Wacker Chemie AG: WACKER Strengthens Its Pharmaceutical-Protein Business and Buys Dutch Biotechnology Plant
DGAP-News: Wacker Chemie AG / Key word(s): Mergers & Acquisitions
Wacker Chemie AG: WACKER Strengthens Its Pharmaceutical-Protein Business and
Buys Dutch Biotechnology Plant
17.04.2018 / 08:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- WACKER TAKES OVER SYNCO BIO PARTNERS OF AMSTERDAM
- CAPACITY OF ACQUIRED FERMENTATION PLANT FOR PHARMACEUTICAL ACTIVES TOTALS
SOME 2,000 LITERS - WACKER BIOTECH'S OVERALL CAPACITY DOUBLES AS A RESULT
- SYNCO'S EXPERTISE IN MANUFACTURING LIVE MICROBIAL PRODUCTS AND IN FILLING
FINISHED PHARMACEUTICALS EXPANDS WACKER'S PORTFOLIO
- PLANT ACQUISITION IS A KEY STEP FOR WACKER, SUPPORTING ONGOING EXPANSION
IN THE HIGH-GROWTH BIOPHARMACEUTICALS MARKET AND SECURING SUFFICIENT GMP
PRODUCTION CAPACITIES FOR EXISTING AND NEW CUSTOMERS
Munich and Amsterdam, April 17, 2018 - Wacker Chemie AG has acquired a Dutch
site for manufacturing biopharmaceuticals, live microbial products and
vaccines, plus the associated business, from SynCo Bio Luxembourg S.à.r.l..
The Munich-based chemical company announced the acquisition today. For
WACKER, maintaining SynCo's existing customer relationships is a top
priority. Moreover, WACKER is keeping on SynCo's employees. Both parties
have agreed not to disclose the purchase price."This strategic acquisition
is a key step for our ongoing expansion in the high-growth
biopharmaceuticals market," explained Auguste Willems of WACKER's Executive
Board. "The new plant will enable us to satisfy robust market demand today
and in the coming years - and to strengthen our position as a leading
contract manufacturer of microbial-derived biopharmaceutical proteins."
Founded in 2000, SynCo Bio Partners has some 110 employees and operates two
fermentation lines with current capacities of 1,500 and 270 liters. These
lines manufacture microbial-derived biopharmaceuticals, not only for
clinical testing, but also for the commercial market. There is a further
line of single-use fermenters, which provides additional and flexible
production capabilities. SynCo's service offering is rounded out with a
"fill and finish" facility, which enables the complete manufacture of
pharma-ceuticals from the active agent to the filled product. The facilities
meet "Good Manufacturing Practice" (GMP) quality standards, and they have
already been inspected by the European Medicines Agency (EMA) and the US
Food and Drug Administration (FDA) and approved for the manufacture of
specific pharmaceutical proteins.
"Expanding our production capacity strengthens our market position
sustainably," said Gerhard Schmid, president of WACKER BIOSOLUTIONS. "The
additional fermentation lines double our current capacity, which increases
our ability to produce key pharmaceuticals cost effectively, using advanced
microbial techniques. We look forward to continuing the comprehensive
support for SynCo's existing customers, while also offering them the
proprietary technologies of Wacker Biotech. The acquisition will
significantly expand our portfolio of technologies and services."
SynCo's expertise in manufacturing live microbial biopharmaceuticals is a
valuable complement to WACKER's know-how as a full-service supplier. Live
microbial products represent a promising new class of actives, offering
innovative therapies for serious illnesses and new vaccines against cholera,
for example.
About Wacker Biotech
Wacker Biotech GmbH is a full-service contract manufacturer of
bio-pharmaceutical proteins based on microbial systems. The company's
services range from molecular biology, analytical services and process
development through to the GMP-compliant manufacture of clinical test
samples and pharmaceutical actives for the commercial market at its
German-based Jena and Halle plants, which are GMP compliant, and FDA and EMA
certified. Above all, Wacker Biotech offers proprietary technolo-gies that
satisfy market needs for cost-efficient production and maximum quality.
Wacker Biotech is a wholly-owned WACKER subsidiary.
For further details, please visit the following website:
http://www.wacker.com/biologics
For further information, please contact:
Wacker Chemie AG
Media Relations & Information
Christof Bachmair
Tel. +49 89 6279-1830
[email protected]
---------------------------------------------------------------------------
17.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Wacker Chemie AG
Hanns-Seidel-Platz 4
81737 München
Germany
Phone: 0049-89-6279-1633
Fax: 0049-89-6279-2933
E-mail: [email protected]
Internet: www.wacker.com
ISIN: DE000WCH8881
WKN: WCH888
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
675003 17.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Wacker Chemie AG ISIN: DE000WCH8881 können Sie bei EQS abrufen
Chemie , WCH888 , WCH , XETR:WCH